I recently attended the First International Granulosa Cell Tumor Conference, a gathering of women and caregivers of a rather unique subgroup of ovarian cancer know as GCT Survivors. Conceived by the Granulosa Cell Tumour Foundation of New Zealand, it was the very first time the micro survivor group, families and clinicians joined forces to better understand this obscure, deadly disease.
Granulosa cell tumors, or GCT as they're referred to in the scant literature about them, represent about 5 percent of total ovarian cancer cases or about 1,200 American women each year. GCTs behave differently from the more common epithelial ovarian cancer, and are consequently less responsive (often non-responsive) to standard ovarian cancer treatments. To survivors like myself, it feels like falling through the cracks.
Indeed, very little is known about the disease and the conference speakers from Harvard Medical to M.D. Anderson Cancer Center confessed there was a void of expertise, new treatment options or effective therapeutics. The only consensus on standard of care is surgery, which for many of us becomes an all too regular event, and eventually a dead end street.
Galvanizing the scattered community is the Granulosa Cell Tumour Foundation of New Zealand, a grassroots organization founded by Sladjana 'Sofi' Crosley, who, when diagnosed, was shocked by the lack of data and the frightening inconsistency among medical professionals. As she and her husband Powel pursued answers, they encountered slivers of resources and patients worldwide. They formed the foundation to weave the pieces together for patient support and to raise funds for research. Sofi finally lost her battle with GCT but not before launching a charity on an international stage.
Hope is on the horizon. A remarkable discovery in 2010 of a mutation of FOXL2, a genetic transcription factor common to virtually all GCTs, suggests that, unlike other cancers, solving one piece of the puzzle could benefit nearly all affected women. However, the smallness of the population exacerbates the funding challenge.
GCT symptoms, like all ovarian cancers, are vague.